<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04431687</url>
  </required_header>
  <id_info>
    <org_study_id>A98_02DDI2004</org_study_id>
    <nct_id>NCT04431687</nct_id>
  </id_info>
  <brief_title>A Clinical Trial to Investigate the Pharmacokinetic Drug Interaction and Safety of CKD-501, D759 and D150 (CKD-393)</brief_title>
  <official_title>A Randomized, Open-label, 2-Part, Multiple-dose, Two-way Crossover Clinical Trial to Evaluate Drug-drug Interactions and Safety Between CKD-501, D759, and D150 in Healthy Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chong Kun Dang Pharmaceutical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chong Kun Dang Pharmaceutical</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Clinical trial to investigate the pharmacokinetic drug interaction and safety of CKD-501,&#xD;
      D759 and D150&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A Randomized, Open-label, 2-Part, Multiple-dose, Two-way Crossover Clinical Trial to Evaluate&#xD;
      Drug-drug Interactions and safety between CKD-501, D759, and D150 in Healthy Adult&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 15, 2020</start_date>
  <completion_date type="Actual">October 26, 2020</completion_date>
  <primary_completion_date type="Actual">July 24, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cmax,ss of CKD-501, D759, D150</measure>
    <time_frame>CKD-501: Day1, Day3, Day4 - Pre-dose(0 hour), Day5 - Pre-dose(0 hour), 0.33, 0.67, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 24hours / D759,D150: Day1, Day3, Day4- Pre-dose(0 hour), Day5- Pre-dose(0 hour), 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 24hours</time_frame>
    <description>Cmax,ss: Maximum concentration of drug in plasma at steady state</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUCtau,ss of CKD-501, D759, D150</measure>
    <time_frame>CKD-501: Day1, Day3, Day4 - Pre-dose(0 hour), Day5 - Pre-dose(0 hour), 0.33, 0.67, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 24hours / D759,D150: Day1, Day3, Day4- Pre-dose(0 hour), Day5- Pre-dose(0 hour), 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 24hours</time_frame>
    <description>AUCtau,ss: Area under the plasma drug concentration-time curve within a dosing interval(τ) at steady state</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cmin,ss of CKD-501, D759, D150</measure>
    <time_frame>CKD-501: Day1, Day3, Day4 - Pre-dose(0 hour), Day5 - Pre-dose(0 hour), 0.33, 0.67, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 24hours / D759,D150: Day1, Day3, Day4- Pre-dose(0 hour), Day5- Pre-dose(0 hour), 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 24hours</time_frame>
    <description>Cmin,ss: Minimum concentration of drug in plasma at steady state</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax,ss of CKD-501, D759, D150</measure>
    <time_frame>CKD-501: Day1, Day3, Day4 - Pre-dose(0 hour), Day5 - Pre-dose(0 hour), 0.33, 0.67, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 24hours / D759,D150: Day1, Day3, Day4- Pre-dose(0 hour), Day5- Pre-dose(0 hour), 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 24hours</time_frame>
    <description>Tmax,ss: Time to maximum plasma concentration at steady state</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t1/2,ss of CKD-501, D759, D150</measure>
    <time_frame>CKD-501: Day1, Day3, Day4 - Pre-dose(0 hour), Day5 - Pre-dose(0 hour), 0.33, 0.67, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 24hours / D759,D150: Day1, Day3, Day4- Pre-dose(0 hour), Day5- Pre-dose(0 hour), 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 24hours</time_frame>
    <description>t1/2,ss: Terminal half-life at steady state</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CLss/F of CKD-501, D759, D150</measure>
    <time_frame>CKD-501: Day1, Day3, Day4 - Pre-dose(0 hour), Day5 - Pre-dose(0 hour), 0.33, 0.67, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 24hours / D759,D150: Day1, Day3, Day4- Pre-dose(0 hour), Day5- Pre-dose(0 hour), 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 24hours</time_frame>
    <description>CLss/F: Apparent Clearance at steady state</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fluctuation of CKD-501, D759, D150</measure>
    <time_frame>CKD-501: Day1, Day3, Day4 - Pre-dose(0 hour), Day5 - Pre-dose(0 hour), 0.33, 0.67, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 24hours / D759,D150: Day1, Day3, Day4- Pre-dose(0 hour), Day5- Pre-dose(0 hour), 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 24hours</time_frame>
    <description>Fluctuation: Peak trough fluctuation within one dosing interval</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vd,ss/F of CKD-501, D759, D150</measure>
    <time_frame>CKD-501: Day1, Day3, Day4 - Pre-dose(0 hour), Day5 - Pre-dose(0 hour), 0.33, 0.67, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 24hours / D759,D150: Day1, Day3, Day4- Pre-dose(0 hour), Day5- Pre-dose(0 hour), 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 24hours</time_frame>
    <description>Vd,ss/F: Apparent Volume of distribution at steady state</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">48</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Sequence 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1: CKD-501 - A single oral dose of 1 tablet under fasting conditions for 5 days.&#xD;
Period 2: CKD-501, D759, D150 - A single oral dose of 4 tablets under fasting conditions for 5 days (CKD-501: 1 tablet, D759: 1 tablet, D150: 2 tablets).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1: CKD-501, D759, D150 - A single oral dose of 4 tablets under fasting conditions for 5 days (CKD-501: 1 tablet, D759: 1 tablet, D150: 2 tablets).&#xD;
Period 2: CKD-501 - A single oral dose of 1 tablet under fasting conditions for 5 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1: D759, D150 - A single oral dose of 3 tablets under fasting conditions for 5 days (D759: 1 tablet, D150: 2 tablets).&#xD;
Period 2: CKD-501, D759, D150 - A single oral dose of 4 tablets under fasting conditions for 5 days (CKD-501: 1 tablet, D759: 1 tablet, D150: 2 tablets).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1: CKD-501, D759, D150 - A single oral dose of 4 tablets under fasting conditions for 5 days (CKD-501: 1 tablet, D759: 1 tablet, D150: 2 tablets).&#xD;
Period 2: D759, D150 - A single oral dose of 3 tablets under fasting conditions for 5 days (D759: 1 tablet, D150: 2 tablets).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CKD 501</intervention_name>
    <description>QD, PO</description>
    <arm_group_label>Sequence 1</arm_group_label>
    <arm_group_label>Sequence 2</arm_group_label>
    <other_name>CKD-501</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>D759, D150</intervention_name>
    <description>QD, PO</description>
    <arm_group_label>Sequence 3</arm_group_label>
    <arm_group_label>Sequence 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CKD-501, D759, D150</intervention_name>
    <description>QD, PO</description>
    <arm_group_label>Sequence 1</arm_group_label>
    <arm_group_label>Sequence 2</arm_group_label>
    <arm_group_label>Sequence 3</arm_group_label>
    <arm_group_label>Sequence 4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Those who voluntarily decide to participate and agree to comply with the cautions&#xD;
             after hearing and fully understanding the detailed description of this clinical trial&#xD;
&#xD;
          2. Healthy adult volunteers aged between 19 and 55-year-old&#xD;
&#xD;
          3. Weight ≥ 50kg (men) or ≥ 45kg (women), with calculated body mass index(BMI) of 18.0 to&#xD;
             30.0 kg/m2&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Those who have history of hypersensitivity to active pharmaceutical ingredient&#xD;
             (Lobeglitazone, Sitagliptin, Metformin) or additives.&#xD;
&#xD;
          2. Those who have clinically significant disease or medical history of Hepatopathy, Renal&#xD;
             dysfunction, Neurological disorder, Immunity disorder, Respiratory disorder,&#xD;
             Genitourinary system disorder, Digestive system disorder, Endocrine system disorder,&#xD;
             Cardiovascular disorder, Blood tumor, Psychical disorder, Severe urinary tract&#xD;
             infection&#xD;
&#xD;
          3. Those who have past medical history of gastrointestinal disorder (Crohn's disease,&#xD;
             ulcerative colitis, etc. except simple appendectomy or hernia surgery), which affect&#xD;
             the absorption of drug&#xD;
&#xD;
          4. Those who have Drug abuse (especially sleeping drugs, central analgesics, opiates or&#xD;
             psychotropic drugs such as psychotropic drugs) or persons with a history of substance&#xD;
             abuse&#xD;
&#xD;
          5. Those who have the test results written below&#xD;
&#xD;
               -  AST, ALT &gt; 1.25 times higher than upper normal level&#xD;
&#xD;
               -  Total bilirubin &gt; 1.5 times higher than upper normal level&#xD;
&#xD;
               -  eGFR (estimated Glomerular Filtration Rate, which is calculated by MDRD) &lt; 60&#xD;
                  mL/min/1.73m2&#xD;
&#xD;
               -  &quot;Positive&quot; or &quot;Reactive&quot; test result of Hepatitis B &amp; C, HIV, RPR&#xD;
&#xD;
               -  Under 5 min resting condition, systolic blood pressure &gt;150 mmHg or &lt;90 mmHg,&#xD;
                  diastolic blood pressure &gt;100 mmHg or &lt;50 mmHg&#xD;
&#xD;
          6. Those who have determined that the abnormal results are clinically significant in the&#xD;
             screening test items (question, vital signs, electrocardiogram, physical test, blood,&#xD;
             urine test, etc.)&#xD;
&#xD;
          7. Those who have participated in other clinical trials within 180 days of the intended&#xD;
             study drug administration and have been administered clinical trial medications&#xD;
             (except for those who have not taken the study medication)&#xD;
&#xD;
          8. Those who has taken a drug (specialized drug, generic drug, herbal medicine, or&#xD;
             nutritional supplement (vitamin, etc.)) within 2 weeks prior to screening (however, if&#xD;
             it is considered that it does not affect the safety and research results of the&#xD;
             subject, as determined by the investigator) You can participate in the test.)&#xD;
&#xD;
          9. Those who donated whole blood within 8 weeks prior to screening, or who donated or&#xD;
             donated components (plasma, platelets) within 4 weeks, and consented to prohibit blood&#xD;
             donation from 30 days after the last dose Not.&#xD;
&#xD;
         10. Those who have continuously consumed more than 21 units/week (1 unit of alcohol = 10 g&#xD;
             = 12.5 mL) within 6 months prior to screening&#xD;
&#xD;
         11. Those who have More than 10 smokers a day within 6 months prior to screening&#xD;
&#xD;
         12. Those who cannot use clinically acceptable contraceptive methods (e.g., infertility&#xD;
             surgery between themselves and partners, intrauterine contraceptive devices, use of&#xD;
             diaphragms or condoms) from the time the drug is administered to the last visit&#xD;
&#xD;
         13. Those who cannot inhibit the diet (especially grapefruit juice, caffeine) that can&#xD;
             affect the absorption, distribution, metabolism, and excretion of the drug from 3 days&#xD;
             before the last administration of the investigational drug to the last visit.&#xD;
&#xD;
         14. Those who have genetic problems such as galactose intolerance, Lapp lactose deficiency&#xD;
             or glucose-galactose malabsorption&#xD;
&#xD;
         15. Those who receive intravenous administration of radioactive iodine contrast agents&#xD;
             (for intravenous urography, venous cholangiography, angiography, computed tomography&#xD;
             using contrast agents, etc.) within 48 hours before the first administration of&#xD;
             investigational product&#xD;
&#xD;
         16. Those who are pregnant or breastfeeding&#xD;
&#xD;
         17. Those who are deemed inappropriate to participate in clinical trial by investigators&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anhye Kim, Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHA University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CHA Bundang Medical Center, CHA University</name>
      <address>
        <city>Seongnam-si</city>
        <state>Bundang</state>
        <zip>13497</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>June 11, 2020</study_first_submitted>
  <study_first_submitted_qc>June 11, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 16, 2020</study_first_posted>
  <last_update_submitted>November 13, 2020</last_update_submitted>
  <last_update_submitted_qc>November 13, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

